
**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549**

**SCHEDULE 14D-9
(Rule 14d-101)**

**SOLICITATION/RECOMMENDATION STATEMENT
UNDER SECTION 14(D)(4) OF THE SECURITIES EXCHANGE ACT OF 1934**

F-Star Therapeutics, Inc.
(Name of Subject Company)

F-Star Therapeutics, Inc.
(Names of Person Filing Statement)

Common Stock, Par Value \$0.0001 Per Share
(Title of Class of Securities)

30315R107
(CUSIP Number)

**Eliot Forster
Chief Executive Officer
Eddeva B920**

**Babraham Research Campus
Cambridge, CB22 3AT, United Kingdom
+44-1223-497400**

(Name, Address and Telephone Number of Person Authorized to Receive Notice and Communications
on Behalf of the Person Filing Statement)

Copies To:

**William C. Hicks, Esq.
Matthew Gardella, Esq.
Mintz, Levin, Cohn, Ferris,
Glovsky and Popeo P.C.
One Financial Center
Boston, MA 02111
617-542-6000**

Check the box if the filing relates solely to preliminary communications made before the commencement of a tender offer.

The information set forth under Items 1.01, 5.02 and 9.01 of the Current Report on Form 8-K filed by F-star Therapeutics, Inc. on June 23, 2022 (including all exhibits attached thereto) is incorporated herein by reference.